Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Lilly's obesity triple threat tops phase 3 efficacy forecasts
Lilly linked its triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee osteoarthritis.
Nick Paul Taylor
Dec 11, 2025 8:15am
Lilly looks to become innovation ‘backbone,’ exec says
Dec 8, 2025 12:05pm
Fierce Pharma
Novo reports 2 trial failures for GLP-1 in Alzheimer's disease
Nov 24, 2025 11:41am
Lilly picks Philadelphia for newest Gateway Labs site
Nov 19, 2025 6:45am
European VC Medicxi closes €500M biotech fund
Nov 14, 2025 3:00am
Lilly continues AI push, inking $100M-plus deal with Insilico
Nov 10, 2025 9:00am
